Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | +5.41% | +0.86% | -9.30% |
14/05 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.30% | 169M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.68% | 238B | |
+7.01% | 204B | |
-6.18% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director